Clinical trials for Prostate cancer

147 currently recruiting clinical trials
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors #NCT05503797 #2024-513578-23-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
BRAF
Required number of previous lines of therapy
1 2 3 or more
Excluded genetic anomalies
HRAS KRAS G12C KRAS non G12C NRAS
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Fore Biotherapeutics
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT03175224 #2024-514542-37-00
Cohortes C, D
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
BRAF EGFR KRAS G12C KRAS non G12C NTRK-1/2/3 RET ALK ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Targeted therapy
5 recruiting sites
Apollomics
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors #NCT03175224 #2024-514542-37-00
Cohorte F
Required number of previous lines of therapy
1 2 3 or more
Excluded genetic anomalies
ALK BRAF EGFR KRAS G12C KRAS non G12C MET NTRK-1/2/3 RET ROS-1
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Apollomics
Phase 2 Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer Stomach and esophageal cancer Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06333314 #2023-505298-34-00
Required histologic sub types
Neuroendocrine carcinoma
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Radiotherapy
7 recruiting sites
UNICANCER
Phase 2 Prostate cancer #NCT07287150 #2025-521327-67-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
4 recruiting sites
Hoffmann-La Roche
Phase 2 Prostate cancer #NCT07016230 #2024-515847-47-00
Required histologic sub types
Neuroendocrine carcinoma
Required disease stage
Metastatic Hormone-sensitive Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT06581432 #2023-510429-14-00
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Boehringer Ingelheim
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT06760819 #2024-517419-62-00
Required histologic types
Stomach Oesogastric junction Esophagus
Required histologic sub types
Adenocarcinoma Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Ampullary carcinoma Gastrointestinal stromal tumor Squamous cell carcinoma Other
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Bayer
Phase 2 Prostate cancer #NCT06866938 #2024-512043-22-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required PSMA PET Scan statuses
PSMA PET Positive
Required previous treatments at advanced or metastatic stage
Chemotherapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Hospices Civils de Lyon
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT03767075 #2024-514238-19-00
Module 2 bras 2B, Module 3 bras 3A et 3C
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
EGFR FGFR MET
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Institut d'oncologie du Vall d'Hebron